Currently, The Tisch Cancer Institute (TCI) offers annual funding to support pilot projects that focus on translational and collaborative research between the TCI cancer research programs through the TCI Developmental Fund Awards.
The TCI Developmental Fund Awards specifically support translational and/or epidemiological projects that are intra- and inter-collaborations between TCI members, with a requirement that the co-Principal Investigators of the projects are TCI members. An independent and dedicated TCI Developmental Fund Award Committee oversees the review and selection process for each Request for Application (RFA). The RFA is created by the TCI Developmental Fund Award Committee Chair, Dr. Stuart Aaronson and emailed to current TCI members.
All TCI projects must comply with all internal and regulatory approval processes before a project account is established. Scientific progress is monitored through a mid-year progress report, which is reviewed by the Committee Chair, and a final report is required. No-cost extensions can be requested, but a justification is required.
2022 TCI Developmental Fund Awardees:
Deborah Doroshow, MD, PhD (Cancer Clinical Investigation); Melissa Mazor, PhD, MS, RN (Cancer Prevention and Control) - Development and Evaluation of a Lay Navigator-Led Intervention for Enhancing Diversity in Early Phase Clinical Trial Enrollment
Deirdre Cohen, MD (Cancer Clinical Investigation); Benjamin Hopkins, PhD (Cancer Mechanisms); Daniela Sia, PhD (Cancer Mechanisms); Anna Tocheva, PhD (Cancer Immunology) - Validating a Patient-Derived Pre-Clinical Model of Intrahepatic Cholangiocarcinoma That Accurately Recapitulates Patient Responses to Identify Novel Immunotherapy-Based Combinations
Daniel Puleston, PhD (Cancer Immunology); Myron Schwartz, MD (Cancer Clinical Investigation) - Novel Approaches to Probe Human Hepatocellular Carcinoma Biology and Therapy Through Normathermic Machine Perfusion of the Liver